Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Standardized assays to monitor drug sensitivity in hematologic cancers.
Ayuda-Durán P, Hermansen JU, Giliberto M, Yin Y, Hanes R, Gordon S, Kuusanmäki H, Brodersen AM, Andersen AN, Taskén K, Wennerberg K, Enserink JM, Skånland SS. Ayuda-Durán P, et al. Among authors: wennerberg k. Cell Death Discov. 2023 Dec 1;9(1):435. doi: 10.1038/s41420-023-01722-5. Cell Death Discov. 2023. PMID: 38040674 Free PMC article.
Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia.
Kuusanmäki H, Kytölä S, Vänttinen I, Ruokoranta T, Ranta A, Huuhtanen J, Suvela M, Parsons A, Holopainen A, Partanen A, Kuusisto MEL, Koskela S, Räty R, Itälä-Remes M, Västrik I, Dufva O, Siitonen S, Porkka K, Wennerberg K, Heckman CA, Ettala P, Pyörälä M, Rimpiläinen J, Siitonen T, Kontro M. Kuusanmäki H, et al. Among authors: wennerberg k. Haematologica. 2023 Jul 1;108(7):1768-1781. doi: 10.3324/haematol.2022.281692. Haematologica. 2023. PMID: 36519325 Free PMC article.
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia.
Kuusanmäki H, Dufva O, Vähä-Koskela M, Leppä AM, Huuhtanen J, Vänttinen I, Nygren P, Klievink J, Bouhlal J, Pölönen P, Zhang Q, Adnan-Awad S, Mancebo-Pérez C, Saad J, Miettinen J, Javarappa KK, Aakko S, Ruokoranta T, Eldfors S, Heinäniemi M, Theilgaard-Mönch K, Wartiovaara-Kautto U, Keränen M, Porkka K, Konopleva M, Wennerberg K, Kontro M, Heckman CA, Mustjoki S. Kuusanmäki H, et al. Among authors: wennerberg k. Blood. 2023 Mar 30;141(13):1610-1625. doi: 10.1182/blood.2021011094. Blood. 2023. PMID: 36508699 Free PMC article.
A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids.
Senkowski W, Gall-Mas L, Falco MM, Li Y, Lavikka K, Kriegbaum MC, Oikkonen J, Bulanova D, Pietras EJ, Voßgröne K, Chen YJ, Erkan EP, Dai J, Lundgren A, Grønning Høg MK, Larsen IM, Lamminen T, Kaipio K, Huvila J, Virtanen A, Engelholm L, Christiansen P, Santoni-Rugiu E, Huhtinen K, Carpén O, Hynninen J, Hautaniemi S, Vähärautio A, Wennerberg K. Senkowski W, et al. Among authors: wennerberg k. Dev Cell. 2023 Jun 19;58(12):1106-1121.e7. doi: 10.1016/j.devcel.2023.04.012. Epub 2023 May 5. Dev Cell. 2023. PMID: 37148882 Free PMC article.
A community effort to assess and improve drug sensitivity prediction algorithms.
Costello JC, Heiser LM, Georgii E, Gönen M, Menden MP, Wang NJ, Bansal M, Ammad-ud-din M, Hintsanen P, Khan SA, Mpindi JP, Kallioniemi O, Honkela A, Aittokallio T, Wennerberg K; NCI DREAM Community; Collins JJ, Gallahan D, Singer D, Saez-Rodriguez J, Kaski S, Gray JW, Stolovitzky G. Costello JC, et al. Among authors: wennerberg k. Nat Biotechnol. 2014 Dec;32(12):1202-12. doi: 10.1038/nbt.2877. Epub 2014 Jun 1. Nat Biotechnol. 2014. PMID: 24880487 Free PMC article.
Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia.
Adnan Awad S, Dufva O, Klievink J, Karjalainen E, Ianevski A, Pietarinen P, Kim D, Potdar S, Wolf M, Lotfi K, Aittokallio T, Wennerberg K, Porkka K, Mustjoki S. Adnan Awad S, et al. Among authors: wennerberg k. Cell Rep Med. 2024 May 21;5(5):101521. doi: 10.1016/j.xcrm.2024.101521. Epub 2024 Apr 22. Cell Rep Med. 2024. PMID: 38653245
Robust scoring of selective drug responses for patient-tailored therapy selection.
Chen Y, He L, Ianevski A, Ayuda-Durán P, Potdar S, Saarela J, Miettinen JJ, Kytölä S, Miettinen S, Manninen M, Heckman CA, Enserink JM, Wennerberg K, Aittokallio T. Chen Y, et al. Among authors: wennerberg k. Nat Protoc. 2024 Jan;19(1):60-82. doi: 10.1038/s41596-023-00903-x. Epub 2023 Nov 23. Nat Protoc. 2024. PMID: 37996540 Review.
PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells.
Denisova OV, Merisaari J, Huhtaniemi R, Qiao X, Yetukuri L, Jumppanen M, Kaur A, Pääkkönen M, von Schantz-Fant С, Ohlmeyer M, Wennerberg K, Kauko O, Koch R, Aittokallio T, Taipale M, Westermarck J. Denisova OV, et al. Among authors: wennerberg k. Mol Oncol. 2023 Sep;17(9):1803-1820. doi: 10.1002/1878-0261.13488. Epub 2023 Jul 26. Mol Oncol. 2023. PMID: 37458534 Free PMC article.
157 results